Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00476827 · ClinicalTrials.gov registry record · Phase 2
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
A Phase 2 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00476827 is a Phase 2 study that was terminated before completion, run by Duke University. The registered enrollment target is 16 participants.
The verdict
NCT00476827, a Phase 2 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Our hypothesis is that this study design, in which bevacizumab is added to one of six single agent chemotherapies with proven activity in metastatic breast cancer, will result in regression or stabilization of this disease in a safe and tolerable manner.
Interventions
- DRUG Bevacizumab
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Vinorelbine Tartrate
- DRUG CPT-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00476827
The ClinicalTrials.gov registry entry for NCT00476827 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00476827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00476827 about?
NCT00476827 is a clinical study titled "A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain". Our hypothesis is that this study design, in which bevacizumab is added to one of six single agent chemotherapies with proven activity in metastatic breast cancer, will result in regression or stabilization of this disease in a safe and tolerable manner.
What is the current status of trial NCT00476827?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2007-05. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00476827?
The interventions under investigation include: Bevacizumab (DRUG), Docetaxel (DRUG), Paclitaxel (DRUG), Vinorelbine Tartrate (DRUG), CPT-11 (DRUG).
Who is sponsoring clinical trial NCT00476827?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.